BRIP1 (FANCJ) germline pathogenic in EOC: established moderate-risk gene (~RR 3-5); inclu...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRIP1-GERMLINE-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | BRIP1 germline pathogenic |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIA |
| Recommended combinations | niraparib maintenance, olaparib + bevacizumab (HRD-positive), rucaparib (LOH-high) |
| Evidence summary | BRIP1 (FANCJ) germline pathogenic in EOC: established moderate-risk gene (~RR 3-5); included in HRR panels and HRD-positive PARPi trial subgroups. NCCN includes BRIP1 in PARPi-eligible HRR list. ESCAT IIA / OncoKB Level 3A. |
Notes
Cascade testing per NCCN. Modest breast-cancer risk in relatives.
Used By
No reverse references found in the YAML corpus.